A drug delivery and development company in California said Thursday it has wrapped an agreement to acquire a CBD beauty, wellness and pet product maker for $20 million.
CURE Pharmaceutical completed its purchase of Sera Labs for $19 million in CURE stock and $1 million in cash, with an additional $4 million of working capital to support Sera Labs’ growth, according to a statement. The deal is expected to close in early October.
With the acquisition, the Oxnard-based company said it foresees reaching a cash-flow positive status in 18 months as Sera takes over the marketing and distribution of CURE’s proprietary, oral dissolvable film health and wellness products. Sera Labs products are sold in major national drug store, grocery chains and mass retailers, the statement said.
“The rest of 2020 will set the stage to make 2021 a breakout year for the Sera Labs wellness business as well as for CURE Pharmaceutical,” CURE CEO Rob Davidson said in a statement.
Nancy Duitch, founder and CEO of Sera Labs, will continue in her role as the CEO and assume the additional role of chief strategic officer of CURE’s Wellness Division.
“With the consummation of the transaction, the Sera Labs’ team is excited to introduce consumers to CURE’s innovative delivery system, which we believe will change the way they take daily nutraceuticals,” Duitch said.
CURE trades on over-the-counter markets as CURR.
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers